New Gene Therapy Could Face Uphill Battle
The potential FDA approval of BioMarin’s gene therapy for hemophilia would be a major win, but patient uptake could be slow.
The potential FDA approval of BioMarin’s gene therapy for hemophilia would be a major win, but patient uptake could be slow.